Latest news with #8.8
Time of India
2 days ago
- Automotive
- Time of India
RTI: Eway e-challan recovery just 9 per cent of 269cr
The Intelligent Traffic Management System (ITMS) on Mumbai-Pune expressway has generated 17 lakh e-challans worth nearly ₹ 269.5 crore for traffic violations since it was implemented on July 19 last year, but recovery from offenders stands at a measly 9per cent till March 2025, officials said on Sunday. The 1.5 lakh cleared e-challans, or 9per cent of the total generated, amount to ₹25.2 crore, which is 9.3 per cent of the total sum to be paid by offenders, as per official documents. As per an RTI reply, Maharashtra government has paid the ITMS operator ₹57.9 crore for the 8.8 lakh e-challans issued between July 19 and Dec 31 last year. The project is being executed by the Maharashtra State Road Development Corporation (MSRDC), which built the Mumbai-Pune expressway, in collaboration with the RTO and highway police under a Public-Private Partnership ( PPP ) model. The state transport department has given ₹45 crore viability gap funding from Road Safety Fund for the project that costs more than ₹100 crore. The MSRTC has installed 40 gantries and hundreds of CCTV cameras as part of ITMS, which also includes speed detection cameras , ANPR, weigh-in-motion sensors, AVCC, weather sensors, and a dynamic messaging system.
Time of India
5 days ago
- Automotive
- Time of India
Mumbai-Pune expressway ITMS flags ₹269 crore in fines, recovers just 9%, ET Infra
Advt Join the community of 2M+ industry professionals. Subscribe to Newsletter to get latest insights & analysis in your inbox. Get updates on your preferred social platform Follow us for the latest news, insider access to events and more. The Intelligent Traffic Management System (ITMS) on Mumbai-Pune expressway has generated 17 lakh e-challans worth nearly ₹269.5 crore for traffic violations since it was implemented on July 19 last year, but recovery from offenders stands at a measly 9 per cent till March 2025, officials said on 1.5 lakh cleared e-challans, or 9 per cent of the total generated, amount to ₹25.2 crore, which is 9.3 per cent of the total sum to be paid by offenders, as per official per an RTI reply, Maharashtra government has paid the ITMS operator ₹57.9 crore for the 8.8 lakh e-challans issued between July 19 and December 31 last project is being executed by the Maharashtra State Road Development Corporation (MSRDC), which built the Mumbai-Pune expressway, in collaboration with the RTO and highway police under a Public-Private Partnership (PPP) state transport department has given ₹45 crore viability gap funding from Road Safety Fund for the project that costs more than ₹100 MSRTC has installed 40 gantries and hundreds of CCTV cameras as part of ITMS, which also includes speed detection cameras, ANPR, weigh-in-motion sensors, AVCC, weather sensors, and a dynamic messaging system.
Mint
02-06-2025
- Business
- Mint
India's GDP: A key test lies ahead
The fiscal policy-led rescue of India's economy from the covid shock has been impressive, even though its pace of expansion slowed to 6.5% in 2024-25, as provisional data shows, after a three-year run averaging above 8.8%. Last year's rate of GDP growth dropped below the path demanded by Viksit Bharat, but the second half's acceleration reveals a grip on its gear-stick held by the government through public expenditure. How long, though, will state support last? Also Read: Kaushik Basu: Redefine prosperity; GDP tunnel-vision could prove costly Last year's fiscal gap was under 4.8% and this year's 4.4% goal is achievable. After that, public debt will be adopted as the official gauge to constrain risky over-spending. Also Read: It's time to lay the great Indian GDP controversy to rest Clearly, India's Fiscal Responsibility and Budget Management (FRBM) law needs rework in the light of lessons from our economic recovery. How 2025-26 turns out may be instructive. If inflation stays subdued at around 4%, the central bank's aim, even with the fiscal deficit exceeding the FRBM's 3% cap, it'll be a relief. Also Read: The state of India's economy is not as bright as GDP data may suggest What happens to price stability if private investment and consumption regain full strength, however, remains untested. It's a key test, as faster growth and lower debt require both these to form a robust mutually reinforcing loop.
Business Insider
23-05-2025
- Health
- Business Insider
Cullinan Therapeutics to present new results from REZILIENT1 trial
Cullinan Therapeutics (CGEM), Taiho Pharmaceutical and Taiho Oncology announced new results from the pivotal Phase 2b cohorts of the REZILIENT1 trial, a Phase 1/2 clinical trial of zipalertinib monotherapy in patients with advanced or metastatic non-small cell lung cancer with epidermal growth factor receptor exon 20 insertion mutations who have received prior therapy. These data will be presented on Sunday, June 1 at the American Society of Clinical Oncology annual meeting as an oral presentation. As of the December 2024 data cutoff, 244 patients were enrolled in REZILIENT1 and received at least one dose of 100 mg zipalertinib. The overall efficacy population consisted of all patients who received at least one dose of 100 mg zipalertinib and had approximately 8 months of minimum follow-up at data cutoff. Patients had received a median of 2 prior therapies, and 39% of patients had a history of brain metastases. With median follow-up of 9.3 months, zipalertinib demonstrated: In the overall efficacy population, confirmed overall objective response rate was 35% with median duration of response of 8.8 months; in patients with prior platinum-based chemotherapy only, ORR was 40% with mDOR of 8.8 months, consistent with REZILIENT1 Phase 1/2a results; in patients with prior chemo and amivantamab, ORR was 30% with mDOR of 14.7 months; in patients with prior chemo and amivantamab, ORR was 24% with mDOR of 8.5 months and in patients with brain metastases, the ORR was 31% with mDOR of 8.3 months. The safety analysis population included all REZILIENT1 patients who received at least one dose of 100 mg zipalertinib. The results showed that zipalertinib demonstrated a manageable safety profile in this heavily pre-treated patient population, consistent with previously reported data. The most common treatment-related adverse events were paronychia, rash, dermatitis acneiform, dry skin, diarrhea and stomatitis. The majority of TRAEs were grade 1 or 2. The most common grade 3 TRAEs were anemia, pneumonitis and rash, increased alanine aminotransferase, diarrhea, and decreased platelet count.
Winnipeg Free Press
16-05-2025
- Winnipeg Free Press
Tokyo customs make what is believed to be Japan's largest bust of ketamine
TOKYO (AP) — Tokyo police and customs have made what is believed to be their biggest bust of the anesthetic drug ketamine, brought through Haneda airport in a suitcase. On Friday Tokyo customs officials said they filed a criminal complaint against a French woman on suspicion of attempting to smuggle into Japan about 40 kilograms (88 pounds) of ketamine in a suitcase. The suspect, whom the officials identified as a 21-year-old cook, was caught at the Haneda airport customs after arriving on a flight from Germany in April, officials at Tokyo Customs said. The drug found in the suitcase has a street value of about 920 million yen ($8.8 million), according to Japan's NHK television. Ketamine is a powerful anesthetic approved by U.S. health regulators for use during surgery. It can be given as an intramuscular injection or by IV. The drug is used recreationally for its euphoric effects and can cause hallucinations or impact breathing and the heart.
